Bringing patient-specific tumor targeted immunotherapies to
the world, one patient
at a time.
At Geneos, our passion is to develop Exquisitely Personalized Immunotherapies to unleash the most powerful force against Cancer: your body’s own immune system.
We have established our GT-EPIC™ Platform to drive development of individualized treatments.
Our approach is to target unique neoantigens (abnormal mutations and genomic variations produced by cancer cells) from individual patient tumors to develop novel treatments for cancer. Our technology is designed to identify relevant neoantigen targets and then design, manufacture, and deliver tumor- specific neoantigen-targeted personalized immunotherapies.
Geneos addresses the heterogeneous nature of cancer by leveraging its powerful, proprietary, immunotherapy platform, GT-EPIC™, to develop tumor-specific neoantigen targeted personalized immunotherapies
The GT-EPIC™ platform drives T cells, and in particular, antigen specific CD8+ T cells with a killing function. Tumor targeted T cells are the key effectors of tumor cell death
Please stay tuned for a list of upcoming conferences Geneos will be attending.
Geneos will be attending the following upcoming conferences:
- NeoAntigen Based Therapies Summit
October 24-26, 2022
- American Association for the Study of Liver Diseases (AASLD)
November 4-8, 2022
- Society for the Immunotherapy of Cancer (SITC)
November 8-12, 2022